Clinical Asthma Phenotypes and Therapeutic Responses
Table 1
Laboratory and demographic data of the studied groups.
G1
G2
G3
G4
P1
P2
P3
P4
P5
P6
FEV1% predicted
1.3
1.2
1.1
<0.001*
0.8
<0.001*
<0.001*
<0.001*
<0.001*
Total sIgE (IU/mL)
14.9
30.3
17.6
12.59
<0.001*
<0.001*
<0.001*
<0.001*
<0.001*
<0.001*
Peripheral eosinophilic%
0.69
0.83
1.08
0.71
<0.001*
0.1
<0.001*
<0.001*
<0.001*
0.03
sECP (µg/L)
7.05
12.38
8.25
5.19
<0.001*
<0.001*
<0.001*
<0.001*
<0.001*
<0.001*
sICAM-1 (ng/mL)
56.4
70.9
62.2
<0.001*
0.9
0.3
<0.001*
0.2
<0.001*
sVCAM-1 (ng/mL)
269.1
230.2
239.2
<0.001*
0.7
0.8
<0.001*
0.3
<0.001*
sIL-2R (pg/mL)
379.1
544.05
349.2
<0.001*
0.3
<0.001*
<0.001*
<0.001*
<0.001*
Age (y)
2.3
2.3
1.2
0.22
0.66
0.66
0.66
0.66
0.66
0.66
Male
25 (52.08%)
23 (53.4%)
27 (51.92%)
21 (47.72%)
0.6
0.6
0.6
0.6
0.6
0.6
Female
23 (47.9%)
20 (46.51%)
25 (48.07%)
23 (52.27%)
0.62
0.62
0.62
0.62
0.62
0.62
Duration of asthma (y)
0.71
0.71
0.71
FH: positive
28 (58.3%)
24 (55.81%)
29 (55.76%)
Negative
FH: negative
20 (41.6%)
19 (44.18%)
23 (44.23%)
Negative
Data are expressed as mean (SD); * is considered significant. IgE: immunoglobulin E, sECP: serum eosinophilic cationic protein, and FH: family history of asthma. G1: shortness of breath group (SOB) group, G2: cough group, G3: Wheezy group, and G4: controls. P1 : G2 versus G4, P2 : G2 versus G3, P3 : G2 versus G1, P4 : G3 versus G4 , P5: G3 versus G1, and P6 : G1 versus G4.
